To view quote, trade, company profile, news and filing information, please enable javascript on your browser.
Diamyd Medical AB - DMYDY
OTCQX International / Security Type:
Business Description
Diamyd Medical's lead drug candidate, Diamyd, is designed for treatment for both Type I (end of Phase II) and LADA Type 2 diabetes (Phase II). Other developments include a proprietary Nerve Targeted Drug Delivery System to deliver genes coding for the GAD or Enkephalin to treat diabetes pain and neuropathy (pre-clinical phase).
Officers and Directors
| Anders Essen-Moller |
Chairman |
| Darren Wolfe |
CEO |
| Bjorn O. Nilsson |
Dir. |
| Peter Rothschild |
Dir. |
| Hans Wigzell |
Dir. |
| Elisabeth Lindner |
President |
| Anna Styrud |
Director, Fin. |
| Peter Zerhouni |
Director, Bus. Dev. |
| Natalie Jelveh |
Director, Business Control |
| Erika Hillborg |
Director of Development |
Service Providers
Auditor/Accountant
|
Legal Counsel
|
Investor Relation Firm
|
Other Information
| Industry Classification |
2834 - Pharmaceutical preparations |
| Jurisdiction of Incorporation |
,SWE |
| Year of Incorporation |
1996 |
| CIK |
0001344485 |
| Non Exchange Listing |
OMX Nordic Exchange Stockholm |
| Market Cap |
4.700402032E8 |
| Shares Outstanding |
28660988 |
